Daniel I Prez

List of Publications by Year in Descending Order

49 papers	1,901 citations	26 h-index	43 g-index
53 ext. papers	2,127 ext. citations	6.1 avg, IF	4.5 L-index

#	Paper	IF	Citations
49	Improved Controlled Release and Brain Penetration of the Small Molecule S14 Using PLGA Nanoparticles. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	7
48	Developing novel classes of protein kinase CK1δ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems. *European Journal of Medicinal Chemistry*, **2021**, 216, 113331	6.8	3
47	Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis. *European Journal of Medicinal Chemistry*, **2021**, 210, 112968	6.8	9
46	Increasing Brain Permeability of PHA-767491, a Cell Division Cycle 7 Kinase Inhibitor, with Biodegradable Polymeric Nanoparticles. *Pharmaceutics*, **2021**, 13,	6.4	7
45	In Vitro and In Silico Acetylcholinesterase Inhibitory Activity of Thalictricavine and Canadine and Their Predicted Penetration across the Blood-Brain Barrier. *Molecules*, **2019**, 24,	4.8	13
44	Computer-aided molecular design of pyrazolotriazines targeting glycogen synthase kinase 3. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2019**, 34, 87-96	5.6	8
43	A Triazolotriazine-Based Dual GSK-3β/CK-1ε Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition. *ChemMedChem*, **2019**, 14, 310-314	3.7	16
42	1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2018**, 33, 665-670	5.6	18
41	Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. *Journal of Medicinal Chemistry*, **2017**, 60, 4983-5001	8.3	36
40	Biological and Pharmacological Characterization of Benzothiazole-Based CK-1δ Inhibitors in Models of Parkinson's Disease. *ACS Omega*, **2017**, 2, 5215-5220	3.9	7
39	Targeting TDP-43 phosphorylation by Casein Kinase-1δ inhibitors: a novel strategy for the treatment of frontotemporal dementia. *Molecular Neurodegeneration*, **2016**, 11, 36	19	37
38	Application of BACE1 immobilized enzyme reactor for the characterization of multifunctional alkaloids from Corydalis cava (Fumariaceae) as Alzheimer's disease targets. *Fitoterapia*, **2016**, 109, 241-7	3.2	23
37	New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of Aspergillus fumigatus growth. *European Journal of Medicinal Chemistry*, **2016**, 116, 281-289	6.8	7
36	Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3β Inhibitors. *Journal of Medicinal Chemistry*, **2016**, 59, 531-44	8.3	73
35	Small GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating Autophagy. *PLoS ONE*, **2016**, 11, e0162723	3.7	10
34	In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier. *Journal of Natural Products*, **2015**, 78, 1189-92	4.9	24
33	3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease. *ACS Chemical Neuroscience*, **2015**, 6, 1665-82	5.7	47

32	Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors. *Angewandte Chemie - International Edition*, **2015**, 54, 1578-82	16.4	87
31	Multitarget Drug Discovery for Alzheimer's Disease: Triazinones as BACE-1 and GSK-3β Inhibitors. *Angewandte Chemie*, **2015**, 127, 1598-1602	3.6	5
30	From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer's Disease. *Current Medicinal Chemistry*, **2015**, 22, 3789-806	4.3	18
29	Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. *Journal of Medicinal Chemistry*, **2014**, 57, 2755-72	8.3	70
28	Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors. *Journal of Medicinal Chemistry*, **2014**, 57, 8590-607	8.3	18
27	Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. *ACS Chemical Neuroscience*, **2013**, 4, 350-60	5.7	47
26	Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. *European Journal of Medicinal Chemistry*, **2013**, 60, 479-89	6.8	47
25	A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimer's and Prion Diseases. *ACS Medicinal Chemistry Letters*, **2013**, 4, 225-9	4.3	36
24	Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. *Neurobiology of Aging*, **2013**, 34, 2133-45	5.6	64
23	Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease. *Current Topics in Medicinal Chemistry*, **2013**, 13, 1808-19	3	28
22	Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. *European Journal of Medicinal Chemistry*, **2012**, 47, 175-85	6.8	53
21	A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation. *European Journal of Medicinal Chemistry*, **2012**, 48, 206-13	6.8	22
20	5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3β [GSK-3β] and phosphodiesterase 7 (PDE7) inhibitors: determination of blood-brain barrier penetration and binding to human serum albumin. *European Journal of Pharmaceutical Sciences*, **2012**, 45, 677-84	5.1	20
19	Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice. *ACS Chemical Neuroscience*, **2012**, 3, 793-803	5.7	18
18	Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds. *Journal of Medicinal Chemistry*, **2012**, 55, 3274-84	8.3	43
17	Microwave-assisted synthesis of hydroxyphenyl nitrones with protective action against oxidative stress. *European Journal of Medicinal Chemistry*, **2012**, 58, 44-9	6.8	13
16	5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. *Journal of Medicinal Chemistry*, **2012**, 55, 1645-61	8.3	61
15	Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. *Journal of Medicinal Chemistry*, **2011**, 54, 8461-70	8.3	78

14	Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment. *International Journal of Alzheimer's Disease*, **2011**, 2011, 280502	3.7	60
13	The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy. *Current Medicinal Chemistry*, **2011**, 18, 3028-34	4.3	24
12	Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. *Journal of Medicinal Chemistry*, **2011**, 54, 4042-56	8.3	60
11	Immobilization of horseradish peroxidase as crosslinked enzyme aggregates (CLEAs). *Process Biochemistry*, **2011**, 46, 765-769	4.8	72
10	Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. *Medicinal Research Reviews*, **2011**, 31, 924-54	14.4	98
9	An application of two MIFs-based tools (Volsurf+ and Pentacle) to binary QSAR: the case of a palinurin-related data set of non-ATP competitive glycogen synthase kinase 3 (GSK-3) inhibitors. *European Journal of Medicinal Chemistry*, **2011**, 46, 860-9	6.8	22
8	PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury. *PLoS ONE*, **2011**, 6, e15937	3.7	52
7	Cross-Linked Enzyme Aggregates of Chloroperoxidase: Synthesis, Optimization and Characterization. *Advanced Synthesis and Catalysis*, **2009**, 351, 2133-2139	5.6	36
6	Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 6914-25	3.4	44
5	The first enantioselective synthesis of palinurin. *Chemical Communications*, **2009**, 3252-4	5.8	22
4	Visible light-driven and chloroperoxidase-catalyzed oxygenation reactions. *Chemical Communications*, **2009**, 6848-50	5.8	103
3	PDE7 inhibitors as new drugs for neurological and inflammatory disorders. *Expert Opinion on Therapeutic Patents*, **2008**, 18, 1127-1139	6.8	37
2	GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?. *Journal of Alzheimer's Disease*, **2008**, 15, 181-91	4.3	105
1	Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching. *Journal of Medicinal Chemistry*, **2003**, 46, 4631-3	8.3	92